InCerebro
InCerebro is a Seoul-based pharmaceutical R&D company that combines quantum mechanics algorithms and AI through its MIND platform to offer drug target identification, molecular dynamics simulation, and binding affinity prediction services, serving pharmaceutical and biotech firms via SaaS, joint research, and technology licensing.
- Company typePrivate
- Founded2019
- HeadquartersSeoul, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What InCerebro does
InCerebro (주식회사 인세리브로) is a Seoul-based pharmaceutical research and development company founded in 2019 that operates a proprietary computational drug discovery platform combining quantum mechanics algorithms, molecular dynamics simulation, and artificial intelligence. The company's flagship offering is the MIND (Molecular Interaction Dynamics) platform, which comprises specialized modules including QM/MM Docking, Water Pharmacophore generation, FIT Screening, multiple AIMD (Ab Initio Molecular Dynamics) simulations for globular proteins, membrane receptors, protein-protein interactions (PPI), lipid nanoparticles (LNP), and PROTAC molecules, along with MIND-BAR for binding affinity regression. The company has commercialized MIND-QUBE, a cloud-based SaaS product for binding free energy prediction that claims a 30x+ speed improvement over conventional methods.
InCerebro generates revenue through three channels: SaaS subscriptions on MIND-QUBE, joint research collaborations with new drug development companies, and platform technology licensing of its proprietary Water Pharmacophore and FIT Screening methods. The company operates a direct B2B sales motion targeting pharmaceutical and biotech enterprises primarily in South Korea, with primary offices in Seoul (Seongdong-gu headquarters and Gangnam-gu registration address). It maintains an active scientific publication program with at least 8 peer-reviewed papers in journals including Nature Scientific Reports, ACS Medicinal Chemistry Letters, Journal of Molecular Graphics and Modelling, and Experimental & Molecular Medicine, focused on GPCR and membrane protein research.
The company is privately held and venture-backed, having raised approximately ₩6.05 billion (~$4.5M USD) across a 2021 pre-A round led by HB Investment and two 2024 third-party private placements from the SUP-Unicorn Fostering Investment Fund and SUP-3 Private Investment Fund. As of 2026, InCerebro operates with 11-50 employees and is actively hiring computational chemists, AI specialists, and software engineers, signaling a scale-up phase ahead of broader MIND-QUBE commercialization. The company has received the Korea Industry Awards K-First Class Award for three consecutive years, reflecting sustained domestic industry recognition.
InCerebro firmographics
Firmographics- Name
- InCerebro
- Legal name
- 주식회사 인세리브로
- Website
- https://incerebro.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- InCerebro is a Seoul-based pharmaceutical R&D company that combines quantum mechanics algorithms and AI through its MIND platform to offer drug target identification, molecular dynamics simulation, and binding affinity prediction services, serving pharmaceutical and biotech firms via SaaS, joint research, and technology licensing.
- Ownership category
- akta.pro rank
InCerebro industry classification
Industry- Product category
- Drug Discovery Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand) (HDAGAEAB), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
Keywords
Where InCerebro is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices1 record
Markets served
InCerebro business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- MIND-QUBE SaaS Platform: Cloud-based SaaS subscription model offering binding free energy prediction and drug discovery computational services to pharmaceutical and biotech companies. The company commercializes its proprietary quantum mechanics and AI-driven platform through software-as-a-service subscriptions.
- Joint Research & Co-development: Revenue generated through collaborative drug discovery research projects with new drug development companies, utilizing InCerebro's proprietary platform technologies.
- Platform Technology Licensing: Technology licensing arrangements for InCerebro's proprietary drug design platform capabilities including Water Pharmacophore generation and FIT Screening technologies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
InCerebro product offering
Product offeringCore offering
InCerebro sells the MIND (Molecular Interaction Dynamics) in-silico drug discovery platform, which combines quantum mechanics software, molecular dynamics simulation, and AI algorithms to accelerate drug target identification and candidate substance development for pharmaceutical and biotechnology clients. The company also offers MIND-QUBE, a cloud-based SaaS version of the platform that performs binding free energy predictions more than 30x faster than conventional methods, and engages in joint research collaborations and platform technology licensing with new drug development companies.
Product overview
inCerebro is a drug development company founded in 2019 offering a platform-based portfolio centered on the MIND (Molecular Interactions and Dynamics) drug discovery platform. MIND is an in-silico target modeling and drug discovery platform that combines quantum mechanics software with AI and molecular dynamics for accelerated drug development. The platform comprises specialized modules including QM/MM Docking for quantum-based binding simulation, Water Pharmacophore and FIT Screening for candidate identification, and multiple AIMD (Ab Initio Molecular Dynamics) modules targeting Globular proteins, Membrane receptors, Protein-Protein Interactions (PPI), Lipid Nanoparticles (LNP), and PROTAC molecules. The MIND-BAR module provides binding affinity ranking through free energy calculations. Key differentiated offerings include the proprietary Water Pharmacophore generation technology, FIT Screening technology, and MIND-QUBE SaaS—a binding free energy prediction solution that achieves 30x+ computational speed improvement. The platform leverages quantum mechanics algorithms and AI for reduced research time compared to traditional methods.
Differentiator
Problem solved
Functional benefit
Products and services
- MIND Drug Discovery Platform Flagship in-silico target modeling and drug discovery platform combining quantum mechanics software, AI, and molecular dynamics for accelerated drug target and candidate substance development. Sold to pharmaceutical and biotechnology R&D organizations.
- MIND-QUBE SaaS Cloud-based SaaS binding free energy prediction solution built on the MIND platform that achieves more than 30x computational speed improvement over conventional methods for drug discovery free energy calculations.
- Joint Drug Discovery Research Services Collaborative drug discovery research services using the MIND platform, sold to new drug development enterprises under joint research and co-development arrangements.
- Platform Technology Licensing Licensing of proprietary MIND platform capabilities, including Water Pharmacophore generation and FIT Screening technologies, to pharmaceutical and biotechnology partners.
Quantifiable outcome
- Calculation speed improved by more than 30x compared to conventional binding free energy prediction methods
Companies that use InCerebro
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
InCerebro technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
InCerebro partnerships and signals
Strategic signalScale indicators3 records
Recent moves5 records
Expansion highlights5 records
InCerebro competitors and assessment
Company assessmentDirect peers
- Exscientia: AI-driven drug design company combining generative AI with experimental automation. Direct peer in offering AI-augmented drug discovery to pharma, including target-to-candidate workflows.
- Atomwise: AI-driven small molecule drug discovery platform partnering with pharma on target identification and hit generation. Direct overlap in offering computational drug discovery as a service to pharma/biotech clients.
- Schrödinger, Inc. Computational chemistry and drug discovery platform with physics-based FEP+ binding free energy prediction (a direct functional analog of MIND-QUBE) and AI-augmented molecular design. Schrödinger is the closest large-scale comparable to InCerebro's MIND platform.
- Insilico Medicine: End-to-end AI drug discovery company using generative chemistry and target identification. Comparable in offering AI/ML-driven candidate generation and validation, with broader end-to-end pipeline coverage.
- XtalPi: Combines AI with quantum physics-based molecular simulation for drug discovery and crystal structure prediction, directly overlapping with InCerebro's quantum-mechanics + AI architecture. Operates at significantly larger scale across China and the US.
- BenevolentAI: AI platform for drug discovery with emphasis on target identification and drug repurposing. Comparable in offering AI-augmented discovery services to pharma/biotech partners.
Emerging players
- Cyrus Biotechnology: Computational protein engineering platform offering protein design and structure prediction software. Partial overlap with InCerebro's protein-structure AIMD modules and drug discovery focus.
- Iambic Therapeutics: AI-driven drug discovery combining physics-based modeling with neural networks for small molecule design. Emerging peer with overlapping physics+AI architecture and comparable size to InCerebro.
Broad incumbents
- Simulations Plus: Provider of computational modeling and simulation software for pharmaceutical R&D, including physiologically-based pharmacokinetic modeling. Adjacent incumbent with established pharma software footprint.
- Recursion Pharmaceuticals: Techbio platform combining high-throughput biology with AI/ML for drug discovery. Broader scope (target ID through development) and substantially larger scale, but overlapping in using computational methods to accelerate pharma R&D.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
InCerebro social profiles
Digital presenceInCerebro financial estimates
Financial estimateRevenue estimate
Valuation estimate
InCerebro leadership team
Management profileNumber of profiles
Profiles1 record
InCerebro funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
InCerebro M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about InCerebro
What does InCerebro do?
InCerebro sells the MIND (Molecular Interaction Dynamics) in-silico drug discovery platform, which combines quantum mechanics software, molecular dynamics simulation, and AI algorithms to accelerate drug target identification and candidate substance development for pharmaceutical and biotechnology clients. The company also offers MIND-QUBE, a cloud-based SaaS version of the platform that performs binding free energy predictions more than 30x faster than conventional methods, and engages in joint research collaborations and platform technology licensing with new drug development companies.
Is InCerebro a public or private company?
InCerebro is a private company. It is classified as venture growth investor backed and is currently operating.
When was InCerebro founded?
InCerebro was founded in 2019. It employs 11 to 50 people.
Where is InCerebro based?
InCerebro is headquartered in Seoul, South Korea, in the Asia region.
How does InCerebro make money?
Three revenue lines are on record. MIND-QUBE SaaS Platform is the primary driver. The others are joint Research & Co-development and platform Technology Licensing.
Who are InCerebro's main competitors?
Direct peers on record are Exscientia, Atomwise, Schrödinger, Inc., Insilico Medicine, XtalPi and BenevolentAI. Emerging players are Cyrus Biotechnology and Iambic Therapeutics. Broad incumbents are Simulations Plus and Recursion Pharmaceuticals.
Does InCerebro have an API?
No public API is recorded for InCerebro.
What industry is InCerebro in?
InCerebro's product category is Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 541714 and its SIC code is 8731.